cefixime has been researched along with Fever of Unknown Origin in 1 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
Fever of Unknown Origin: Fever in which the etiology cannot be ascertained.
Excerpt | Relevance | Reference |
---|---|---|
"The objective of this study was to test the efficacy of oral ciprofloxacin in the treatment of lower risk febrile neutropenia (LRFN) in children treated for malignant diseases." | 9.09 | Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. ( Armada, A; Cáceres, E; Casimir, L; Debbag, R; Fernández, C; Firpo, V; Latella, A; Paganini, H; Rodriguez-Brieshcke, T; Zubizarreta, P, 2001) |
"The objective of this study was to test the efficacy of oral ciprofloxacin in the treatment of lower risk febrile neutropenia (LRFN) in children treated for malignant diseases." | 5.09 | Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. ( Armada, A; Cáceres, E; Casimir, L; Debbag, R; Fernández, C; Firpo, V; Latella, A; Paganini, H; Rodriguez-Brieshcke, T; Zubizarreta, P, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Paganini, H | 1 |
Rodriguez-Brieshcke, T | 1 |
Zubizarreta, P | 1 |
Latella, A | 1 |
Firpo, V | 1 |
Casimir, L | 1 |
Armada, A | 1 |
Fernández, C | 1 |
Cáceres, E | 1 |
Debbag, R | 1 |
1 trial available for cefixime and Fever of Unknown Origin
Article | Year |
---|---|
Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
Topics: Administration, Oral; Adolescent; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antineopla | 2001 |